---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005235"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:29:28.887230+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech reports Q3 net loss of $1.7M; advances EB06 manufacturing for vitiligo Phase 2

## Summary
- Net loss of $1.7M ($0.25/sh) for quarter ended June 30, 2025, unchanged from $1.7M ($0.52/sh) YoY.
- Operating expenses flat at $1.9M; R&D $0.9M, G&A $1.0M.
- Cash and cash equivalents $12.4M, working capital $12.1M at June 30, 2025.
- EB06 Phase 2 vitiligo IND data submission to FDA planned by end of calendar 2025; manufacturing activities ongoing.
- EB05 program benefits from fully funded U.S. government platform study; first randomizations completed.

## SEC filing metadata
- accession: 0001171843-25-005235
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184325005235/0001171843-25-005235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184325005235/f8k_080825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005235
- JSON: https://secwatch.observer/filing/0001171843-25-005235.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005235.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.